Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462293 | 0.84 | POLB (0.71) | LMNAPOLBKDM4EAPEX1TDP1 | |
| SCHEMBL3007153 | 0.83 | KDM4E (0.71) | LMNAPOLBKDM4EAPEX1TDP1 | |
| SCHEMBL23595909 | 0.76 | KMT2A (0.55) | HTTMEN1KMT2ATP53 | |
| SCHEMBL19661666 | 0.75 | CYP1A2 (0.53) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27950463 | 0.75 | LMNA (0.50) | LMNAPOLBKDM4EAPEX1TDP1 | |
| SCHEMBL23420635 | 0.73 | POLB (0.44) | LMNAPOLBKDM4EAPEX1TDP1 | |
| SCHEMBL19120569 | 0.73 | CYP1A2 (0.50) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11652228 | 0.73 | SMN1; SMN2 (0.68) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2857382 | 0.71 | LMNA (0.53) | LMNAPOLBTDP1CYP1A2CYP2C9 | |
| SCHEMBL23595905 | 0.70 | KMT2A (0.51) | LMNAKDM4ETDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| CN-101094832-A | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2007-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | LMNA 4666/4885POLB 4298/4885KDM4E 3327/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | LMNA 2594/4885POLB 2425/4885KDM4E 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.